To discern possible implications of the labelled AT2 cells in the Scgb1a1 model, we included all GFP+ cells from a second intermediate sample—4 weeks after Ad-EA—as well as all GFP+ tumour cells from late-stage tumour nodules (Fig. 5a and Supplementary Fig. 5a) and performed scRNA-seq. The gene discussed is SCGB1A1; the disease is neoplasm.